Noticias de ARQT_US

Mercado

Noticias del mercado

Últimas noticias sobre ARQT_US — 133 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ARQT_US ✕ 133 resultados
15/10/2026 ARQT_US — Stock Traders Daily ES ← EN
(ARQT) Movimiento como entrada en conjuntos de señales cuánticas

Price-action only: Arcutis Biotherapeutics Inc. (ARQT) movements set the tone for institutional models. (ARQT) Movement as an Input in Quant Signal Sets

15/10/2026 ARQT_US — Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

13/10/2026 ARQT_US — BigGo Finance
Arcutis CEO Frank Watanabe: Zoryve's $525M Guidance Rests on a Clinician-Led Revolt Against Topical Steroids

Arcutis Biotherapeutics CEO Frank Watanabe is betting that a 70-year clinical habit is finally breaking. Speaking on Citeline's Strategic Intent…

13/10/2026 ARQT_US — Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Stock forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

11/10/2026 ARQT_US — Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, News, Quote & History

Find the latest Arcutis Biotherapeutics, Inc. (ARQT) stock quote, history, news and other vital information to help you with your stock trading and investing.

11/10/2026 ARQT_US — Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

09/10/2026 ARQT_US — The Manila Times
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to New analyses from the ARRECTOR and DERMIS-1/2 trials further...

09/10/2026 ARQT_US — The Manila Times
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to New analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE

Página 2 de 7